Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

2024-06-11

PONTE VEDRA, Fla., June 11, 2024 /PRNewswire/ --

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today announced that the Company will be participating in the Emerging Growth Conference on June 12, 2024.

Management will deliver a webcasted presentation and subsequently open the floor to questions during the Conference. Cadrenal's presentation will be on Wednesday, June 12, 2024, at 10:50 am ET. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE.

If attendees are not able to join the event live on the day of the Conference, an archived webcast will also be made available on www.EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.

Management will also host one-on-one investor meetings after the Conference. To request a virtual one-on-one meeting with the Company's management team, please contact your respective Emerging Growth Conference representative or email the Company's investor relations team at [email protected].

ABOUT CADRENAL THERAPEUTICS, INC.

Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions who require lifelong anticoagulation. Tecarfarin has orphan drug designation from the FDA for the prevention of thrombosis and thromboembolism (blood clots) in patients with an implanted mechanical circulatory support device, which includes the left ventricular assist device (LVAD). Tecarfarin also has orphan drug and fast-track designations from the FDA for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Tecarfarin is specifically designed to use a different metabolism pathway than the oldest and most commonly prescribed VKA warfarin. Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.

For more information, please contact:

Cadrenal Therapeutics:

Matthew Szot, CFO

858-337-0766

[email protected]

Investors:

Lytham Partners, LLC

Robert Blum, Managing Partner

602-889-9700

[email protected]

SOURCE Cadrenal Therapeutics, Inc.

更多内容，请访问原始网站